IPLEXMED
PrivateLast Round
Accelerator
Jan 13, 2025
Total Funding Raised
$351,000
Company Overview
IPLEXMED operates in Healthcare & Life Sciences and is based in Braga. Its latest recorded funding round was an Accelerator round in January 2025.
IPLEXMED is a medtech company that develops portable genetic diagnostic devices designed to provide lab-grade results for health support.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Sensors, Precision Medicine, Health IoT
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales, Hardware + Subscription
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IPLEXMED Comparables
Compare IPLEXMED with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GRIP Molecular Technologies | 82% | |
| IdentifySensors Biologics | 81% | |
| Anavasi Diagnostics | 79% |
For institutional investors. Book with your work email.
IPLEXMED Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Jan 13, 2025 | ||||
| Grant | Sep 27, 2023 | ||||
| Grant | May 23, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
IPLEXMED Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EIT Health | Grant |
| BIC Gipuzkoa | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 11, 2025
Monthly visitors grew 273% MoM to 1.3K.
- Sep 27, 2023
$54K grant received from EIT Health
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 27, 2026
Iplexmed is to represent Portugal at the eAwards international final in Portugal in Nov '26, where national winners from Europe and Latin America compete for a €100,000 prize.
- is_developingOct 27, 2026
Iplexmed is developing NEXAGUARD(R), a portable and connected molecular diagnostic solution that uses graphene sensors, disposable cartridges, and artificial intelligence to support faster diagnosis of respiratory infections and antimicrobial resistance.
- receives_awardOct 27, 2026
Iplexmed wins the eAwards Portugal 2026, promoted by the NTT DATA Foundation, in Lisbon, Portugal, on Oct 27th '26 with NEXAGUARD, a portable platform that identifies more than 30 respiratory pathogens in about 20 minutes.
For institutional investors. Book with your work email.
IPLEXMED Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about IPLEXMED's valuation, stock price, and market status.
Is IPLEXMED a public or private company?
IPLEXMED is a private company.
What is the current stock price of IPLEXMED?
IPLEXMED is a private company, so its shares have no public market price. Caplight tracks IPLEXMED's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is IPLEXMED worth (valuation)?
Valuation information for IPLEXMED is not publicly available.
Can I buy IPLEXMED stock?
IPLEXMED shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was IPLEXMED's last funding round?
IPLEXMED's most recent funding round was Accelerator on January 13, 2025.
Who are the main investors in IPLEXMED?
Key investors in IPLEXMED include EIT Health, BIC Gipuzkoa.
Will IPLEXMED IPO soon?
No public IPO plans have been announced for IPLEXMED.
How can I track IPLEXMED secondary market activity?
Caplight tracks bids, offers, and trades in IPLEXMED's shares on secondary markets.